The efficacy of cancer immunotherapy in NSCLC is hampered by neoantigen loss or intra-tumor heterogeneity for neoantigens, by the development of an immunosuppressive microenvironment secondary to tumor aneuploidy and by constitutive, non-immuno-mediated, tumor PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.